首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Up-regulation of interleukin-8, interleukin-10, monocyte chemotactic protein-1, and monocyte chemotactic protein-3 in peripheral blood monocytes in stable lung transplant recipients: are immunosuppression regimens working?
【24h】

Up-regulation of interleukin-8, interleukin-10, monocyte chemotactic protein-1, and monocyte chemotactic protein-3 in peripheral blood monocytes in stable lung transplant recipients: are immunosuppression regimens working?

机译:稳定肺移植受者外周血单核细胞中白细胞介素8,白细胞介素10,单核细胞趋化蛋白1和单核细胞趋化蛋白3的上调:免疫抑制方案是否有效?

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Alveolar macrophages are a major source of inflammatory cytokines and chemokines involved in the pathogenesis of lung transplant rejection and are derived from blood monocytes that migrate to the lung. Levels of monocyte cytokines and chemokines that may be relevant in transplant rejection have not previously been determined in transplant recipients. We hypothesized that production of these inflammatory mediators by blood monocytes may be up-regulated despite the use of potent immunosuppression therapy. METHOD: To investigate this, whole blood from 9 stable lung transplant recipients and 12 control volunteers was stimulated with lipopolysaccharide in vitro, and intracellular chemokine and cytokine production were determined with multiparameter flow cytometry. RESULTS: Monocyte production of chemokines interleukin (IL)-8, monocyte chemotactic protein (MCP)-1, and MCP-3, and anti-inflammatory cytokine IL-10 were significantly increased in the lung transplant group, but IL-6, tumor necrosis factor-alpha, IL-1alpha, IL-12, macrophage inflammatory protein-1alpha, macrophage inflammatory protein-1beta, and transforming growth factor-beta levels were unchanged. CONCLUSIONS: Because MCP-3 is a major chemoattractant for leukocytes to sites of antigenic challenge and is a natural ligand for MCP-1 receptor, this novel finding has important implications for the pathogenesis of lung transplant rejection. We now provide evidence that current immunosuppression protocols have a limited effect on monocyte inflammatory cytokine production and do not adequately suppress monocyte IL-8, MCP-1, and MCP-3 chemokine production. Drugs that modulate the action of these chemokines may improve current protocols for reducing graft rejection. Intracellular chemokine and cytokine analysis with flow cytometry may be a more accurate indicator of immunosuppression than drug levels in these patients.
机译:背景:肺泡巨噬细胞是参与肺移植排斥反应发病机制的炎性细胞因子和趋化因子的主要来源,并来源于迁移至肺的血液单核细胞。与移植排斥有关的单核细胞细胞因子和趋化因子水平以前尚未在移植接受者中确定。我们假设尽管使用了有效的免疫抑制疗法,但血液单核细胞产生的这些炎性介质可能会被上调。方法:为对此进行研究,体外用脂多糖刺激来自9位稳定的肺移植受者和12位对照志愿者的全血,并通过多参数流式细胞术确定细胞内趋化因子和细胞因子的产生。结果:在肺移植组中,趋化因子白介素(IL)-8,单核细胞趋化蛋白(MCP)-1和MCP-3的单核细胞生成以及抗炎细胞因子IL-10显着增加,而IL-6,肿瘤坏死因子-alpha,IL-1alpha,IL-12,巨噬细胞炎性蛋白-1alpha,巨噬细胞炎性蛋白-1beta和转化生长因子-beta水平不变。结论:由于MCP-3是白细胞向抗原性攻击位点的主要趋化因子,并且是MCP-1受体的天然配体,因此这一新发现对肺移植排斥的发病机理具有重要意义。我们现在提供证据,当前的免疫抑制方案对单核细胞炎性细胞因子的产生具有有限的影响,并且不能充分抑制单核细胞IL-8,MCP-1和MCP-3趋化因子的产生。调节这些趋化因子作用的药物可以改善目前减少移植排斥的方案。在这些患者中,流式细胞术进行细胞内趋化因子和细胞因子分析可能是比药物水平更准确的免疫抑制指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号